Journal of Clinical Psychopharmacology

JCP keeps clinician-scientists and trainees up-to-date on the latest clinical developments in psychopharmacologic agents.

Our podcast:

[Journal of Clinical Psychopharmacology @JCPjournal]

With no FDA-approved medications currently available for #methamphetamine use disorder, new research offers encouraging safety data for #mirtazapine.

Read more in JCP: 🔗 https://t.co/xWFfkPeUFr

[Journal of Clinical Psychopharmacology @JCPjournal]

Can high-dose #propranolol be used safely in #autism spectrum and related developmental disorders? In a retrospective review of 52 patients receiving doses up to 1200 mg/day, investigators found no serious cardiac adverse events over 8 years.
Read more: 🔗 https://t.co/kfOZldIsCP

[Journal of Clinical Psychopharmacology @JCPjournal]

New clinical data show that botanical #kratom was generally well tolerated in this pilot study, but higher doses produced opioid-like effects and increased ratings of drug liking and feeling “high.”

Read more in JCP: 🔗 https://t.co/6crBjthDJb

[Journal of Clinical Psychopharmacology @JCPjournal]

📢 Our July/August 2026 issue (Volume 46, issue 4) is now available online: https://t.co/VcQv4ynbNs

[Journal of Clinical Psychopharmacology @JCPjournal]

Can boosting #serotonin #synthesis improve outcomes when SSRIs are not enough? Our latest review and podcast explore five decades of evidence for serotonin synthesis amplification as an #augmentation strategy.

🎧Podcast: https://t.co/ixIhkma2Bm
📰Article: https://t.co/TYQhyEOlz8

[Journal of Clinical Psychopharmacology @JCPjournal]

🏆2025 Mitchell B. Balter Award goes to “The Association Between Stimulant Medication Use and Mortality”

This study found an association between stimulant use and mortality and reinforces cardiovascular risk assessment guidance.

Congrats to Morrow et al.
https://t.co/Rz1mEvOq03

[Journal of Clinical Psychopharmacology @JCPjournal]

#Lithium remains first-line for #bipolar disorder, but these two cases published in JCP highlight that sinus #bradycardia can occur at therapeutic levels in patients without #cardiac disease, may be asymptomatic, and is rapidly reversible.

🔗 Read more: https://t.co/zHn2X9Axef

[Journal of Clinical Psychopharmacology @JCPjournal]

What if we've been overlooking a promising treatment for low #sexual desire in #men? Our new editorial and podcast revisits #bremelanotide (Vyleesi) for sexual desire and arousal disorders in men.

🎧 Podcast: https://t.co/iqIpskSg3Y
📜 Editorial: https://t.co/uolCguvnPD

[Journal of Clinical Psychopharmacology @JCPjournal]

A new international survey of healthcare providers found SSRIs remain the most common first-line treatment for MDD, while augmentation with atypical antipsychotics increases with greater illness severity and inadequate antidepressant response.
🔗Read more: https://t.co/LaW69ujH6b

[Journal of Clinical Psychopharmacology @JCPjournal]

Why is it so hard to find psychiatrists well-trained in #psychopharmacology? Our recent editorial argues the problem isn’t just workforce shortages, but also gaps in residency training, supervision, and evaluation.

🎧 https://t.co/Zqj5SC4gSL
📜 https://t.co/pZwckxYdID

[Journal of Clinical Psychopharmacology @JCPjournal]

The CADET Trials are evaluating whether #candesartan, a commonly prescribed antihypertensive medication, may serve as a novel adjunctive treatment for bipolar and major depressive disorder by targeting the renin-angiotensin system.

Read more in JCP: 🔗 https://t.co/WzdlCKUFLS

[Journal of Clinical Psychopharmacology @JCPjournal]

New real-world evidence shows that adding GLP-1 receptor agonists to second-generation antipsychotic treatment in nondiabetic adults may do more than address weight gain – it may also improve adherence.

🔗Read more in our current issue: https://t.co/FaXcFv3KFQ

[Journal of Clinical Psychopharmacology @JCPjournal]

In a large real-world study of #pediatric #PTSD, psychotherapy was underused, while antidepressants and antipsychotics were frequently prescribed, often without prior therapy. Significant racial and ethnic disparities were observed.

🔗Read more: https://t.co/Z71WeczgOm

[Journal of Clinical Psychopharmacology @JCPjournal]

Our May/June 2026 issue (Volume 46, issue 3) is now available online: https://t.co/8Zb1MSaJqF

Brief synopsis of the new issue from the Journal of Clinical Psychopharmacology Editor-in-Chief is below.

[Journal of Clinical Psychopharmacology @JCPjournal]

Findings from a new study show that #methylphenidate significantly reduces emotional impulsivity in medication-naive children with #ADHD without comorbidities, supporting its potential as a first-line treatment without the need for additional medications.

https://t.co/sasTKdOKFy

[Lippincott Medicine @LippincottMed]

Alcohol Use Disorder treatment is evolving.

A new review explores the potential role of GLP‑1 receptor agonists in supporting AUD care—highlighting how science continues to expand treatment options. https://t.co/s62n3JiuL4 #AlcoholAwarenessMonth #AUDResearch @JCPjournal

[Journal of Clinical Psychopharmacology @JCPjournal]

In a new case report in JCP, semaglutide, a GLP-1 receptor agonist, was associated with sustained remission of gambling behavior in a patient with gambling disorder. This case highlights a potential new pharmacologic pathway targeting reward systems.

🔗 https://t.co/AtoznC1mKY

[Journal of Clinical Psychopharmacology @JCPjournal]

Our new podcast explores trends in #tardive #dyskinesia diagnosis and use of #VMAT2 inhibitors among adults treated with #antipsychotics. The study finds #TD remains underdiagnosed and treatment rates remain low.
🎧Listen: https://t.co/JHpcQi3JXC
📜Read: https://t.co/U6BnnHOwnA

[Journal of Clinical Psychopharmacology @JCPjournal]

The Journal of Clinical Psychopharmacology is building a presence on Bluesky, and we’d love for our LinkedIn community to be part of it. Follow us on Bluesky Social for early updates, featured research, and insight into psychopharmacology trends. 📲 https://t.co/clWsz8wG7Q

[Journal of Clinical Psychopharmacology @JCPjournal]

Why is it so hard to find psychiatrists well-trained in #psychopharmacology? Our new editorial argues the problem isn’t just workforce shortages, but also gaps in residency training, supervision, & evaluation.

🎧Podcast: https://t.co/BGHQGwhJJk
📰Article: https://t.co/S9wVTujYvS